跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

SML3020

Sigma-Aldrich

Taltirelin acetate

≥98% (HPLC)

别名:

(4S)-Hexahydro-1-methyl-2,6-dioxo-4-pyrimidinecarbonyl-L-histidyl-L-prolinamide, (S)-N-((S)-1-((S)-2-Carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide, (S)-N-[(Hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide, TA 0910, TA-0910, TA0910

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H23N7O5 · xC2H4O2
分子量:
405.41 (free base basis)
UNSPSC代码:
12352107
NACRES:
NA.77

产品SML3020监管中,请联系销售询价或购买 联系技术服务部门

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to off-white

储存温度

−20°C

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
SML2849930539SML2978
Taltirelin ≥98% (HPLC)

SML2849

Taltirelin

d9A-2 ≥98% (HPLC)

SML2978

d9A-2

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

-

Quality Level

100

Quality Level

100

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

color

white to off-white

color

white to off-white

color

-

color

white to beige

生化/生理作用

Taltirelin (TA-0910) is a thyrotropin-releasing hormone (TRH) mimetic with greatly enhanced brain-penetration, oral activity and stability. Taltirelin shortens the duration of pentobarbital-induced sleep (0.3-3 mg/kg po. or 0.03-0.3 mg/kg iv.), antagonizes reserpine-induced hypothermia (1 or 3 mg/kg po. or 0.1-0.3 mg/kg ip.), and enhances the spontaneous motor activity (30 mg/kg po.) in mice in vivo, while TRH produces these effects at about 100 times higher doses.
Thyrotropin-releasing hormone (TRH) mimetic with greatly enhanced brain-penetration, oral activity, stability and in vivo efficacy than TRH.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

  • 历史批次信息供参考:

    分析证书(COA)

    Lot/Batch Number

    It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

    如需帮助,请联系 客户支持

    已有该产品?

    在文件库中查找您最近购买产品的文档。

    访问文档库

    John P Dougherty et al.
    Behavioural brain research, 360, 255-261 (2018-12-12)
    Fatigue is a common symptom in many diseases and disorders and can reduce quality of life, yet lacks an adequate pharmacological intervention. To identify and develop such interventions, and to better understand fatigue, additional preclinical research is necessary. However, despite
    Cong Zheng et al.
    Frontiers in cellular neuroscience, 12, 485-485 (2019-01-09)
    Dopaminergic neurons loss is one of the main pathological characters of Parkinson's disease (PD), while no suitable neuroprotective agents have been in clinical use. Thyrotropin-releasing hormone (TRH) and its analogs protect neurons from ischemia and various cytotoxins, but whether the
    M Yamamura et al.
    Japanese journal of pharmacology, 53(4), 451-461 (1990-08-01)
    Effects of orally administered TA-0910, a new thyrotropin-releasing hormone (TRH) analog, on the central nervous system (CNS) were investigated and compared with those of TRH. TA-0910 shortened the duration of pentobarbital-induced sleep and antagonized reserpine-induced hypothermia at 0.3 mg/kg or

    我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系技术服务部门